Leena H Bajrai

InstitutionKing Abdulaziz University
AddressJeddah
Saudi Arabia
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 7 Covid-19 publications, with a maximum of 2 publications in February 2021
    All Publications
    Bar chart showing 10 publications over 3 distinct years, with a maximum of 5 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Alshukairi AN, Tolah AM, Dada A, Al-Tawfiq JA, Almagharbi RS, Saeedi MF, Al-Hamzi MA, El-Kafrawy SA, Bahaudden HA, El-Saed A, Al-Mozaini MA, Khalid I, Hefni LK, Hassan AM, Alandijany TA, Bajrai LH, Bayumi DT, Albishi GE, Althawadi SI, Zabani NA, Perlman S, Azhar EI. Test-based de-isolation in COVID-19 immunocompromised patients: Cycle threshold value versus SARS-CoV-2 viral culture. Int J Infect Dis. 2021 Jul; 108:112-115. PMID: 34004329.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    2. Alsayed SM, Alandijany TA, El-Kafrawy SA, Hassan AM, Bajrai LH, Faizo AA, Mulla EA, Aljahdali LS, Alquthami KM, Zumla A, Azhar EI. Pattern of Respiratory Viruses among Pilgrims during 2019 Hajj Season Who Sought Healthcare Due to Severe Respiratory Symptoms. Pathogens. 2021 Mar 08; 10(3). PMID: 33800223.
      Citations:    
    3. Bharadwaj S, El-Kafrawy SA, Alandijany TA, Bajrai LH, Shah AA, Dubey A, Sahoo AK, Yadava U, Kamal MA, Azhar EI, Kang SG, Dwivedi VD. Structure-Based Identification of Natural Products as SARS-CoV-2 Mpro Antagonist from Echinacea angustifolia Using Computational Approaches. Viruses. 2021 02 15; 13(2). PMID: 33672054.
      Citations: 3     Fields:    Translation:AnimalsCells
    4. Ahmed WA, Dada A, Alshukairi AN, Sohrab SS, Faizo AA, Tolah AM, El-Kafrawy SA, Bajrai LH, Moalim HM, Aly MH, Aboelazm AF, Al-Hamzi MA, Saeedi MF, Alandijany TA, Azhar EI. Seroprevalence of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers in Makkah, Saudi Arabia. J King Saud Univ Sci. 2021 May; 33(3):101366. PMID: 33613011.
      Citations: 4     
    5. Sohrab SS, El-Kafrawy SA, Abbas AT, Bajrai LH, Azhar EI. In Silico Prediction and Designing of Potential siRNAs to be used as Antivirals Against SARS-CoV-2. Curr Pharm Des. 2021; 27(32):3490-3500. PMID: 33430748.
      Citations: 1     Fields:    Translation:Humans
    6. Azhar EI, Hindawi SI, El-Kafrawy SA, Hassan AM, Tolah AM, Alandijany TA, Bajrai LH, Damanhouri GA. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang. 2021 Jul; 116(6):673-681. PMID: 33277935.
      Citations: 4     Fields:    Translation:Humans
    7. Bharadwaj S, Azhar EI, Kamal MA, Bajrai LH, Dubey A, Jha K, Yadava U, Kang SG, Dwivedi VD. SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs. J Biomol Struct Dyn. 2020 Nov 05; 1-16. PMID: 33150855.
      Citations: 5     Fields: